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Summary
Hev b 13 is an allergenic esterase obtained from the rubber tree Hevea brasil-
iensis, which has been shown recently to induce human monocytes to release
interleukin (IL)-10 in vitro, and to exert a potent anti-inflammatory effect
in vivo. Moreover, Hev b 13 has been shown to reduce clinical signs of
inflammation and also histological damage to the distal colon of mice with
2,4,6-trinitrobenze sulphonic acid (TNBS)-induced colitis after its oral
administration. The aim of this study was to investigate the effect of Hev b 13
on human mononuclear cells, as well as its therapeutic use in the methylated
bovine serum albumin (mBSA) model of antigen-induced arthritis. Five days
before the intra-articular challenge, and daily thereafter for 8 days, Hev b 13
was administered by oral gavage. In mice treated with a dose of 0·5 mg/kg of
Hev b 13, the severity of oedema, leucocyte infiltration, pannus formation and
cartilage erosion were reduced significantly. These findings underscore the
anti-inflammatory activity suggested previously for Hev b 13, an activity
speculated to be related to its interaction with monocytes/macrophages and
the consequent stimulation of IL-10 release and reduction of tumour necrosis
factor (TNF) release. The study also opens a wide range of possible applica-
tions in the field of immune-mediated inflammatory diseases.
Keywords: arthritis, Hev b 13, interleukin-10, methylated bovine serum
albumin, tumour necrosis factor
Accepted for publication 23 February 2012
Correspondence: L. B. Teixeira, Department of
Biochemistry and Immunology, Faculty of
Medicine of Ribeirao Preto, University of São
Paulo, 3900 Bandeirantes Avenue, 14049-900,
Ribeirao Preto, São Paulo, Brazil.
E-mail: larissadbt@usp.br
E-mail address of senior author:
jcnetto@fmrp.usp.br (J. Coutinho-Netto)
Introduction
The early nodule-specific protein homologue, or Hev b 13, is
a 391-amino acid glycoprotein obtained from the rubber tree
Hevea brasiliensis. The protein is allergenic, recognized by
immunoglobulin E in sera from latex-allergic patients, and
possesses lipase and esterase activities, which might be asso-
ciated with plant defence [1,2].
Hev b 13 has been shown recently to strongly induce
human mononuclear cells to release interleukin (IL)-10, an
immunoregulatory cytokine, in vitro [3]. Moreover, in an
experimental mouse model of Crohn’s disease, oral admin-
istration of Hev b 13 was shown to have potent anti-
inflammatory activity [4]. However, in-vivo distribution of
the macromolecule after oral administration is unknown in
this model.
IL-10 is known to exert anti-inflammatory effects pre-
dominantly through suppression of the macrophage func-
tion and inhibition of proinflammatory cytokine production
[5–10]. IL-10 has also been implicated as an important
immunoregulator in the cytokine network involved in rheu-
matoid arthritis (RA), because the neutralization of endog-
enously produced IL-10 in diseased synovial membrane
cultures resulted in increased levels of tumour necrosis
factor (TNF)-a and IL-1b [11]. Furthermore, a recent meta-
analysis has indicated an association between IL-10 pro-
moter polymorphisms and susceptibility to RA [12]. This
systemic, chronic inflammatory disease affects 0·5–1% of the
world’s population; its aetiology and pathogenesis show
several of the clinical features of an autoimmune process.
The syndrome is characterized by pain, stiffness and sym-
metrical synovitis of diarthrodial joints, which leads to
articular damage and functional decline, as well as substan-
tial comorbidity in the cardiovascular, neurological and
metabolic systems [13].
Administration of anti-IL-10 antibodies also accelerated
the onset and increased the severity of arthritis in a mouse
model of type II collagen-induced arthritis (CIA) [14,15],
whereas immune augmentation of this cytokine prevents
disease expression and development in CIA [15,16].
Nevertheless, only limited efficacy was observed when
IL-10 was administered systemically to RA patients [17,18].
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Current therapies for RA rely on disease-modifying
anti-rheumatic drugs (DMARDs), such as methotrex-
ate and sulphasalazine, and biological agents [mainly
tumour necrosis factor (TNF) inhibitors]; however, these
approaches are associated with only partial clinical benefit,
as well as toxic adverse effects and high costs. Therefore,
despite the remarkable advances made in recent years, there
is still much progress to be made with regard to treatment
for RA [7,19].
Due to its potent stimulation of IL-10 production
and anti-inflammatory activity we hypothesized that
Hev b 13 may be a preventative for RA, and may
improve joint inflammation. Given this background, we
determined to examine the efficacy of Hev b 13-treatment
in antigen-induced arthritis (AIA). AIA is a T helper type 1
(Th1)-mediated experimental model of joint disease that
follows intra-articular injection of protein antigen [e.g.
methylated bovine serum albumin (mBSA)] into the knee
joints of previously immunized animals [20]. The histo-
pathological appearance of AIA resembles RA, with syn-
ovial hyperplasia, perivascular infiltration of lymphocytes
and plasma cells, lymphoid follicles, pannus and cartilage
erosions [21]. In this study, we therefore investigated the
effect of Hev b 13 on human mononuclear cells and its
potential therapeutic use in the mBSA-induced model
of arthritis.
Materials and methods
Reagents
Histopaque-1077, RPMI-1640 medium, complete and
incomplete Freund’s adjuvants and mBSA were purchased
from Sigma-Aldrich Brasil Ltda (São Paulo, SP, Brazil). Fetal
bovine serum and phytohaemagglutinin were purchased
from Invitrogen Brasil Ltda (São Paulo, SP, Brazil). BD
OptEIATM human interferon (IFN)-g, TNF, IL-6, IL-1b and
transforming growth factor (TGF)-b1 enzyme-linked
immunosorbent assay (ELISA) kits were purchased from
BD-Brasil (São Paulo, SP, Brazil). [3H]-Thymidine (10
Ci/mmol) and the liquid scintillation cocktail OptiPhase
HiSafe 3 were purchased from PerkinElmer do Brasil Ltda
(São Paulo, SP, Brazil).
Obtaining Hev b 13
Hev b 13 was purified as described previously [3]. Briefly,
latex extracted from H. brasiliensis trees (clone RRIM 600)
was coagulated, and the serum so obtained applied to a
diethylaminoethyl (DEAE) cellulose column. The protein
was purified through two further chromatographic steps
(on Asahipak ES-502NP and Sephadex G-50 columns),
after which its identity was determined by peptide mass
fingerprinting and amino-terminal protein sequencing.
Human peripheral blood mononuclear cell
(PBMC) culture
The experimental protocol was approved by the Research
Ethics Committee (HCRP process no. 9575/2010), in com-
pliance with ICH-GCP guidelines, as well as with Resolution
196/96 of the National Health Council (BRA). Informed
consent was signed by healthy blood donors and investiga-
tors prior to beginning the study.
Mononuclear cells (1 ¥ 106/ml) were isolated from whole
venous blood by Ficoll-Hypaque density gradient centrifu-
gation, according to procedures adapted from Böyum [22]
and as described elsewhere [3]. The cells were resuspended
in RPMI-1640 medium with 10% fetal bovine serum,
seeded in 96-well plates in order to assess cytokine produc-
tion. To this end, cells were stimulated in triplicate with
three different concentrations (1, 10 and 100 mg/ml) of Hev
b 13, both in the presence and absence of phytohaemag-
glutinin (PHA; 20 mg/ml). After 72 h of incubation at 37°C
in a saturated humid environment with 5% CO2, superna-
tants were collected and cytokine levels assessed by com-
mercial ELISA kits.
Cell proliferation was also quantified by measuring the
incorporation of [3H]-thymidine (0·5 mCi/well) for an addi-
tional 16-h period [23].
Antigen-induced arthritis in mice
Animals. The animal study protocols (no. 030/2010) were
approved by the Commission of Ethics in Animal Research
of Faculty of Medicine of Ribeirao Preto, University of São
Paulo, according to governmental guidelines for animal care
and experimentation.
Pathogen-free male BALB/c mice, weighing approxi-
mately 25 g, were obtained from the Animal Centre of Uni-
versity of São Paulo. They were housed under controlled
temperature (25°C), humidity (55%) and a 12-h light/dark
cycle, and were given free access to a diet of regular labora-
tory chow and water.
Induction of arthritis and study protocol. Antigen-induced
arthritis was established as described previously, with some
modifications [5]. Briefly, mice were injected subcutaneously
at the back of the neck with 200 ml of an emulsion containing
500 mg of mBSA in phosphate-buffered saline (PBS) and an
equal volume of Freund’s complete adjuvant. Booster injec-
tions of 500 mg of mBSA in Freund’s incomplete adjuvant
were administered subcutaneously in each side of the flank,
after 7 days and again after 14 days. Control, sham-
immunized mice received injections of the same emulsions,
but without mBSA. Arthritis was induced on day 21 by an
intra-articular injection of 50 mg of mBSA in 10 ml of PBS
into the right knee. The left knee, into which 10 ml of PBS
was injected, was used as a control.
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To assess whether early administration of Hev b 13 pro-
tects against development of arthritis, mice receiving antigen
emulsions were randomized to receive water or Hev b 13.
Purified Hev b 13 was administered using oral gavage
(0·5 mg/kg/day) from day 17 after the first immunization to
the end of the experimental period. Mice were euthanized at
days 4, 8 or 13 after the intra-articular challenge.
Macroscopic assessment of arthritis severity. Mice were eutha-
nized by cervical dislocation, and the skin of the knee joint
was removed. Swelling severity was compared between the
two knees and expressed as a clinical score, ranging from 1
to 5, where 1 = no difference between mBSA-injected knee
and the PBS-injected control knee, 2 = slight discoloration
of the mBSA-injected knee, 3 = discoloration of the mBSA-
injected knee and mild lateral swelling, 4 = discoloration of
the mBSA-injected knee and moderate lateral swelling and
5 = discoloration of the mBSA-injected knee to the point
where the ligament is no longer visible and severe lateral
swelling [24]. All scoring was performed by one investigator
(J. C. N.) without knowledge of the treatment protocols.
Histological assessment of arthritis severity. The knee joints
were dissected and fixed in 3·7% buffered formaldehyde.
Fixed tissues were decalcified in formic acid–sodium citrate
reagent [25], dehydrated and embedded in paraffin. Six-mm
sections were deparaffinized with xylene and stained with
Masson’s trichrome, using routine methods. All tissues were
examined in a blinded fashion.
Statistical analysis
A mixed-effects linear regression model, followed by an
orthogonal contrast post-hoc test, was used to compare levels
of cytokines released in response to different levels of
stimulation. For evaluation of clinical score, Kruskal–Wallis
and Dunn’s post-hoc test were used. Statistical analyses were
performed with sas version 9 software (SAS Institute, Inc.,
Cary, NC, USA).
Results
Hev b 13 decreases TNF release without altering cell
proliferation
The effect of Hev b 13 on human PBMCs was investigated by
measuring cell proliferation and cytokine release. The effect
of this stimulus was also evaluated in a T lymphocyte-
enriched population, where PHA had been added as a
specific mitogen.
Figure 1a shows that proliferation rates remain
unchanged after Hev b 13 treatments. The levels of IFN-g in
culture supernatants were also not altered (Fig. 1b). It is
noteworthy, however, that the PHA-stimulation markedly
increased the release of this cytokine.
Conversely, levels of TNF (Fig. 1c) decreased in a
dose-dependent manner in both PHA-stimulated and
unstimulated cells, reaching a 3·5-fold decrease with
100 mg/ml of Hev b 13 and a 1·6-fold decrease with
100 mg/ml of Hev b 13 + PHA compared to basal and PHA
levels, respectively.
IL-6 (Fig. 1d) and IL-1b (Fig. 1e) levels followed a similar
profile in the absence of PHA, with the lower doses of Hev b
13 stimulating an increase in cytokine release and the highest
dose returning the concentration of these cytokines to basal
levels. As shown in Fig. 1e, a 2·6-fold decrease in IL-1b con-
centration occurred at 100 mg/ml of Hev b 13 in the presence
of the mitogen.
TGF-b1 levels (Fig. 1f) were increased significantly by the
1 mg/ml dose of Hev b 13, but also decreased to basal con-
centrations as the protein dose escalated. In an enriched
population, however, none of the tested doses over-
stimulated cytokine release.
Hev b 13 attenuates severity and improves histological
outcome in mBSA-induced arthritis
Previously immunized mice which were subjected to an
intra-articular injection of mBSA developed arthritic
changes in the challenged knee joint, while the contralateral
joint showed no swelling or other pathology. The clinical
signs of inflammation reached a peak on day 8, and were
relieved almost entirely by day 13 (data not shown).
For treatment, a daily oral dose of 0·5 mg/kg of Hev b 13
was chosen after a similar preliminary study, in which doses of
0·5 and 5·0 mg/kg of FrHb 3, the fraction derived from the
first step in the production of purified Hev b 13, had been
administered successfully (results not shown). As illustrated
in Fig. 2, the severity of swelling and discoloration of mBSA-
injected knees was markedly higher among water-treated
mBSA control mice than among Hev b 13-treated mice. It was
noteworthy that no adverse effects, clinical or behavioural,
were observed in animals treated with Hev b 13, suggesting
that this particular dose is probably not toxic in vivo.
Histological examination of the knee joints of mice with
mBSA-induced arthritis revealed severe inflammation and
destruction. As shown in Fig. 3, tissue sections from this
group showed synovial hyperplasia, pannus formation
and cartilage and bone erosion, accompanied by massive
immune cell infiltration (involving mainly lymphocytes and
plasma cells) into the synovial membrane and joint space.
When mice were treated with Hev b 13, a striking improve-
ment in these morphological changes became apparent, with
a significant reduction in the inflammatory activity and leu-
cocyte infiltration (Fig. 3).
Discussion
In the present study we demonstrate, for the first time,
that the early oral administration of Hev b 13 protects mice
Hev b 13 prevents experimental arthritis
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effectively against the development of inflammation in the
mBSA-induced arthritis model, a well-established experi-
mental model that resembles the histopathology of human
RA. After 13 days of treatment with Hev b 13 at a daily dose
of 0·5 mg/kg (12 nmol/kg/day), mice showed significantly
reduced oedema, leucocyte infiltration, cartilage disruption
and fibrovascular ingrowth. These findings underscore the
potent anti-inflammatory effect suggested previously for
Hev b 13 [4], and indicate that the active compound enters
the circulatory system.
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Fig. 1. Effects of Hev b 13 on human peripheral blood mononuclear cells. After 72 h of culture in the absence or presence of phytohaemagglutinin
(PHA; 20 mg/ml), supernatants were collected and tested for the indicated cytokines. An additional 16-h labelling period with [3H]-thymidine was
used to assess proliferation. Cytokine concentration values were normalized to cell proliferation rates. (a) Proliferation rates of cells treated with
Hev b 13 in the absence and presence of PHA. Relative levels of (b) interferon (IFN)-g, (c) tumour necrosis factor (TNF), (d) interleukin (IL)-6, (e)
IL-1b and (f) transforming growth factor (TGF)-b1 in the supernatants of these cells. Data are expressed as means standard error of the mean
(n = 10 individuals per group). **P < 0·01, compared to basal levels (non-stimulated group); ##P < 0·01, compared to PHA-stimulated cells.
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The mechanism of action for Hev b 13 is speculated to be
related to its interaction with immune cells. In a previous
report, we showed that Hev b 13 stimulates human mono-
cytes to release high levels of IL-10 in vitro [3]. By analysing
a panel of cytokines, the present study revealed a major
decrease in TNF levels when PBMCs were cultured in the
presence of 100 mg/ml of Hev b 13, which was followed
numerically by a reduction in the IL-1b levels in super-
natants from T lymphocyte-enriched cell populations.
Whether this immunomodulation is translated into an effec-
tive prevention mechanism for both inflammatory diseases
studied [trinitrobenzene sulphonic acid (TNBS)-induced
colitis [4] and mBSA-induced arthritis] remains to be
determined.
Whether or not the diminished TNF levels are the con-
sequence of IL-10 augmentation by Hev b13 treatment,
reduction of TNF remains a powerful method for control-
ling inflammation. Results from clinical trials with anti-
TNF agents confirm the biological relevance of TNF to the
pathogenesis of chronic non-infectious inflammation of
joints, skin and gut, and places it in the centre of many
converging disease pathways [26]. TNF transduces signals
ranging from cellular activation and proliferation to cyto-
toxicity and apoptosis. Its effector functions include the
ability to induce the production of other proinflammatory
cytokines (including IL-1 and IL-6) and chemokines, which
leads ultimately to leucocyte accumulation in the inflamed
tissue [7].
This study indicates conclusively that Hev b 13 has poten-
tial as an anti-arthritic agent. The results generated in this
and our previous study [3] suggest that the therapeutic
mechanism of Hev b13 may involve stimulation of
monocytes/macrophages to increase release of IL-10 and
decrease release of TNF. This work also highlights some of
many possible applications for Hev b 13, or a fragment of
this protein, in the field of immune-mediated inflammatory
diseases.
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